Manipulation of the renin angiotensin system in peripheral arterial disease

European Journal of Vascular and Endovascular Surgery

Volumn 28, Issue 6, 2004, Pages 573-582

  Hobbs, Simon D ^a   Thomas, M E ^b   Bradbury, A W ^a  

^a NATIONAL HEALTH SERVICE   (United Kingdom)

^b Solihull NHS Trust Teaching   (United Kingdom)

Author keywords

Angiotensin converting enzyme inhibitors; Peripheral arterial disease; Renal artery stenosis

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE; ALPHA 2 GLOBULIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BRADYKININ; CANDESARTAN; CANDESARTAN HEXETIL; CAPTOPRIL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPROSARTAN; IRBESARTAN; LOSARTAN; LOSARTAN POTASSIUM; NONSTEROID ANTIINFLAMMATORY AGENT; OLMESARTAN; PLACEBO; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; RAMIPRIL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SODIUM; TELMISARTAN; TITRACE; UNINDEXED DRUG; VALSARTAN;

ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; ARTERY DISEASE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DIAGNOSTIC PROCEDURE; DOPPLER ECHOGRAPHY; EVIDENCE BASED MEDICINE; GENERAL PRACTITIONER; HEALTH CARE DELIVERY; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; INCIDENCE; KIDNEY ARTERY STENOSIS; KIDNEY FAILURE; KIDNEY SCINTISCANNING; MEDICAL CARE; MEDICAL SPECIALIST; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SECONDARY PREVENTION;

ALGORITHMS; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COMORBIDITY; HUMANS; PERIPHERAL VASCULAR DISEASES; RAMIPRIL; RECEPTORS, ANGIOTENSIN; RENAL ARTERY OBSTRUCTION; RENIN-ANGIOTENSIN SYSTEM;

EID: 7744235528     PISSN: 10785884     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejvs.2004.08.003     Document Type: Review

References (64)

1. P. Burns S. Gough A.W. Bradbury Management of peripheral arterial disease in primary care Br Med J 326 2003 584-588
2. A.V. Kshirsagar M.S. Joy S.L. Hogan et al. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: A systematic overview of randomised placebo-controlled trials Am J Kidney Dis 35 4 2000 695-708
3. AIRE Study Group Effects of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure Lancet 342 1993 821-828
4. R. Garg S. Yusuf Overview of randomised controlled trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials JAMA 273 1995 1450-1456
5. The Heart Outcomes Prevention Evaluation Study Investigators Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients N Engl J Med 342 3 2000 145-153
6. A. Faggiotto R. Paoletti Statins and blockers of the renin-angiotensin system. Vascular protection beyond their primary mode of action Hypertension 34 1999 987-996
7. A.R. Brasier A. Recinos M.S. Eledrisi Vascular inflammation and the renin-angiotensin system Arterioscler Thromb Vasc Biol 22 2002 1257-1266
8. T. Münzel J.F. Kearney Are ACE inhibitors a 'magic bullet' against oxidative stress Circulation 104 2001 1571-1574
9. L. Bell J. Madri Influence of the angiotensin system on endothelial and smooth muscle cell migration Am J Pathol 137 1990 7-12
10. P.E. Tummala X.L. Chen C.L. Sundell et al. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the renin-angiotensin system and atherosclerosis Circulation 100 11 1999 1223-1229
11. T. Omura S. Kim K. Takeuchi et al. Transforming growth factor beta 1 and extracellular matrix gene expression in isoprenaline induced cardiac hypertrophy: Effects of inhibition of the renin-angiotensin system Cardiovasc Res 28 12 1994 1835-1842
12. M.M. Givertz Manipulation of the renin-angiotensin system Circulation 104 2001 e14-e18
13. G. Murphy Matrix metalloproteinases and their inhibitors Acta Orthop Scand Suppl 266 1995 55-60
14. P.M. Vanhoutte C.M. Boulanger S.C. Illiano et al. Endothelium-dependent effects of converting-enzyme inhibitors J Cardiovasc Pharmacol 22 Suppl 5 1993 S10-S16
15. P.M. Vanhoutte Endothelium and control of vascular function: State of the art lecture Hypertension 13 1989 658-667
16. The HOPE Study Investigators The HOPE (Heart Outcomes Prevention Evaluation) study: The design of a large, simple randomised trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events Can J Cardiol 12 2 1996 127-137
17. Peripheral Arterial Diseases Antiplatelet Consensus Group Antiplatelet therapy in peripheral arterial disease. Consensus statement Eur J Vasc Endovasc Surg 26 2003 1-16
18. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial Lancet 360 9326 2002 7-22
19. R. Taylor Conundrum of the HOPE study Br Med J 327 2003 681-682
20. H. Montgomery J. Payne ACE inhibitors: How important are kinins to their actions? In: D.M. Yellon L.H. Opie (Eds.) Cardiology at the limits V 2002 University of Cape Town Press Cape Town 129-145
21. N.J. Brown D.E. Vaughan Angiotensin-converting enzyme inhibitors Circulation 97 1998 1411-1420
22. G.B. Mancini G.C. Henry C. Macaya et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary heart disease: The TREND (trial on reversing endothelial dysfunction) study Circulation 94 1996 258-265
23. E. Lonn S. Yusuf V. Dzavik et al. Effects of ramipril and vitamin E on arteriosclerosis: The Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and Vitamin E (SECURE) Circulation 103 2001 919-925
24. D. Sharma M. Buyse B. Pitt et al. Meta-analysis of observed mortality data from all controlled, double-blind, multiple-dose studies of losartan in heart failure Am J Cardiol 85 2000 187-192
25. B. Pitt P.A. Poole-Wilson R. Segal et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II Lancet 355 9215 2000 1582-1587
26. K. Dickstein J. Kjekshus OPTIMAAL Steering Committee of the OPTIMAAL Study Group Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Optimal trial in myocardial infarction with Angiotensin II Antagonist Losartan Lancet 360 9335 2002 752-760
27. M.A. Pfeffer K. Swedberg C.B. Granger for the CHARM Investigators and Committees Effects of candesartan on mortality and morbidity in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-overall programme Lancet 362 2003 759-766
28. N.K. Hollenburg The treatment of renovascular hypertension: Surgery, angioplasty and medical therapy with converting-enzyme inhibitors Am J Kidney Dis 10 1987 52-60
29. J.F.E. Mann H.C. Gerstein Q.-L. Yi et al. on behalf of the HOPE investigators. Development of renal disease in people at high risk cardiovascular risk: Results of the HOPE randomized study J Am Soc Nephrol 14 2003 641-647
30. J.F.E. Mann H.C. Gerstein J. Pogue on behalf of the HOPE investigators et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial Ann Intern Med 134 2001 629-636
31. P.T. Sawicki S. Kaiser L. Heinemann et al. Prevalence of renal artery stenosis in diabetes mellitus-an autopsy study J Intern Med 229 1991 489-492
32. K.J. Hansen M.S. Edwards T.E. Craven et al. Prevalence of renovascular disease in the elderly: A population-based study J Vasc Surg 36 3 2002 443-451
33. C.G. Missouris T. Buckenham F.P. Cappuccio et al. Renal artery stenosis: a common and important problem in patients with peripheral vascular disease Am J Med 96 1994 10-14
34. J.I. Iglesias R.J. Hamburger L. Feldman et al. The natural history of incidental renal artery stenosis in patients with aortoiliac vascular disease Am J Med 109 2000 642-647
35. P. Salmon M.A. Brown Renal artery stenosis and peripheral arterial disease: Implications for ACE inhibitor therapy Lancet 336 1990 321
36. A.H. Choudhri J.G.F. Cleland P.C. Rowlands et al. Unsuspected renal artery stenosis in peripheral vascular disease Br Med J 301 1990 1197-1198
37. W.J. Jean I. al-Bitar D.L. Zwicke et al. High incidence of renal artery stenosis in patients with coronary artery disease Catheter Cardiovas Diagn 32 1994 8-10
38. G. Ramirez W. Bugni S.M. Farber et al. Incidence of renal artery stenosis in a population having cardiac catheterization South Med J 80 6 1987 734-737
39. C.S. Wilcox Screening for renal artery stenosis: Are scans more accurate than clinical criteria? Ann Intern Med 129 1998 738-740
40. P. Krijnen B.C. van Jaarsveld E.W. Steyerberg et al. A clinical prediction rule for renal artery stenosis Ann Intern Med 129 9 1998 705-711
41. W.R. Pillay Y.M. Kan J.N. Crinnon fet al. or the Joint Vascular Research Group. Prospective multicentre study of the natural history of atherosclerotic renal artery disease in patients with peripheral vascular disease Br J Surg 89 2002 737-740
42. A.S. Levey J.P. Bosch J. Breyer et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group Ann Intern Med 130 6 1999 461-470
43. E.L. Knight R.J. Glynn K.M. McIntyre et al. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: Results from the studies of left ventricular dysfunction (SOLVD) Am Heart J 138 5 1999 849-855
44. G.L. Bakris M.R. Weir Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern? Arch Intern Med 160 2000 685-693
45. A.C. Schoolwerth D.A. Sica B.J. Ballermann et al. Renal considerations in angiotensin converting enzyme inhibitor therapy. A statement for healthcare professionals from the council on the kidney in cardiovascular disease and the council for high blood pressure research of the American Heart Association Circulation 104 2001 1985-1991
46. J. McMurray A. Cohen-Solal R. Dietz et al. Pratical recomendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: Putting guidelines into practice Eur J Heart Fail 3 2001 495-502
47. G.P. Hodsman C.G. Isles G.D. Murray et al. Factors relating to first dose hypotensive effect of captopril: Prediction and treatment Br Med J 286 1983 832-834
48. Z.H. Israili W.D. Hall Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy Ann Intern Med 117 1992 234-242
49. E.E. Slater D.D. Merrill H.A. Guess et al. Clinical profile of angiodema associated with angiotensin converting enzyme inhibition JAMA 260 1988 967-970
50. G.B. Mancini Role of angiotensin-converting enzyme inhibition in reversal of endothelial dysfunction in coronary heart disease Am Heart J 105 1998 40S-47S
51. R. Dietz R. von Harsdorf M. Gross et al. Angiotensin II and coronary heart disease, congestive heart failure, and sudden cardiac death Basic Res Cardiol 93 S2 1998 101-108
52. Z.Q. Jin X. Chen Ramipril-induced delayed myocardial protection against free radical injury involves bradykinin B2 receptor-NO pathway and protein synthesis Br J Pharmacol 125 1998 556-562
53. P.M. Vanhoutte Endothelial dysfunction and inhibition of converting enzyme Eur Heart J 19 1998 J7-J15
54. M.A. Tayeh A.G. Scicli Angiotensin II and bradykinin regulate the expression of P-selectin on the surface of endothelial cells Proc Assoc Am Phys 110 1998 412-421
55. R. Ferrari C. Ceconi S. Curello et al. Cardioprotective effects of angiotensin converting enzyme inhibitors in patients with coronary heart disease Cardiovasc Drugs Ther 10 1996 639-647
56. N.J. Brown M.A. Agirbasli G.H. Williams et al. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1 Hypertension 32 6 1998 965-971
57. W. Metcalfe A.W. Reid C.C. Geddes Prevalence of angiographic atherosclerotic renal artery disease and its relationship to the anatomical extent of peripheral vascular atherosclerosis Nephrol Dial Transplant 14 1 1999 105-108
58. G. Wilms G. Marchal P. Peene et al. The angiographic incidence of renal artery stenosis in the arteriosclerotic population Eur J Radiol 10 3 1990 195-197
59. P. Swartbol B.O. Thorvinger H. Parsson et al. Renal artery stenosis in patients with peripheral vascular disease and its correlation to hypertension. A retrospective study Int Angiol 11 3 1992 195-199
60. P. Swartbol H. Parsson B. Thorvinger et al. To what extent does peripheral vascular disease and hypertension predict renal artery stenosis? Int Angiol 13 2 1994 109-114
61. R. Marin C. Diaz Corte J. Cosio et al. Unsuspected renal artery stenosis in 418 patients with peripheral vascular disease Nefrologia 17 1 1997 62-71
62. K. Wachtell H. Ibsen M.H. Olsen et al. Prevalence of renal artery stenosis in patients with peripheral vascular disease and hypertension J Human Hypertens 10 2 1996 83-85
63. M.B. Harding L.R. Smith S.I. Himmelstein et al.Renal artery stenosis: prevalence and associated risk factors in patients undergoing routine cardiac catheterisation J Am Soc Nephrol 2 11 1992 1608-1616
64. S. Kuroda N. Nishida T. Uzu et al. Prevalence of renal artery stenosis in autopsy patients with stroke Stroke 31 2000 61-65